In last trading session, ProQR Therapeutics N.V (NASDAQ:PRQR) saw 0.61 million shares changing hands with its beta currently measuring 0.18. Company’s recent per share price level of $1.69 trading at -$0.05 or -2.87% at ring of the bell on the day assigns it a market valuation of $174.41M. That closing price of PRQR’s stock is at a discount of -173.37% from its 52-week high price of $4.62 and is indicating a premium of 4.73% from its 52-week low price of $1.61. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.58 million shares which gives us an average trading volume of 414.99K if we extend that period to 3-months.

For ProQR Therapeutics N.V (PRQR), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.16 in the current quarter.

ProQR Therapeutics N.V (NASDAQ:PRQR) trade information

Upright in the red during last session for losing -2.87%, in the last five days PRQR remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $1.69 price level, adding 14.15% to its value on the day. ProQR Therapeutics N.V’s shares saw a change of -36.23% in year-to-date performance and have moved -11.52% in past 5-day. ProQR Therapeutics N.V (NASDAQ:PRQR) showed a performance of -24.55% in past 30-days. Number of shares sold short was 0.9 million shares which calculate 3.22 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 3.75 to the stock, which implies a rise of 54.93% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -18.34% in reaching the projected high whereas dropping to the targeted low would mean a loss of -18.34% for stock’s current value.

ProQR Therapeutics N.V (PRQR) estimates and forecasts

This year revenue growth is estimated to fall -24.65% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 5.84M for the same. And 5 analysts are in estimates of company making revenue of 5.84M in the next quarter. Company posted 5.02M and 7.05M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.74% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -40.76% while estimates for its earnings growth in next 5 years are of -14.28%.

ProQR Therapeutics N.V (NASDAQ:PRQR)’s Major holders

Insiders are in possession of 14.49% of company’s total shares while institution are holding 53.53 percent of that, with stock having share float percentage of 62.60%. Investors also watch the number of corporate investors in a company very closely, which is 53.53% institutions for ProQR Therapeutics N.V that are currently holding shares of the company. PRIVIUM FUND MANAGEMENT B.V. is the top institutional holder at PRQR for having 5.58 million shares of worth $9.21 million. And as of 2024-06-30, it was holding 6.8336 of the company’s outstanding shares.

The second largest institutional holder is ADAGE CAPITAL PARTNERS GP, L.L.C., which was holding about 3.63 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.4394 of outstanding shares, having a total worth of $6.02 million.

On the other hand, Delaware Group Equity Fds IV-Delaware Healthcare Fund and Meridian Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 620.0 shares of worth $1.05 million or 0.76% of the total outstanding shares. The later fund manager was in possession of 520.25 shares on Dec 31, 2024 , making its stake of worth around $0.88 million in the company or a holder of 0.64% of company’s stock.